Short answer
CVS Health (CVS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $108.4B (up 5.4% year over year) with net income of $2.2B.
Q3 2026 key financials · XBRL
- Revenue
- $108.4B
- +5.4% YoY · +2.2% QoQ
- Net income
- $2.2B
- +154.6% YoY · −27.1% QoQ
- Operating margin
- 3.3%
- EPS (diluted)
- $1.68
- +153.5% YoY · −27.3% QoQ
Source: XBRL data from the CVS Health (CVS) Q3 2026 10-Q on SEC EDGAR. USD.
CVS Health Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $108.4B, up 5.4% YoY from $102.9B, driven by Health Services and Health Care Benefits
- Operating margin 3.3% vs (3.1)% YoY, with operating income $3.6B vs $3.2B loss
- Best segment Health Services: revenue $54.0B, up 9.5%; adjusted operating margin 3.9% vs 4.2%
- Worst segment Pharmacy & Consumer Wellness: revenue $35.5B, down 2.0%; adjusted operating margin 4.6% vs 4.1%
- Cash $11.7B; nine-month operating cash flow $15.3B, up $8.1B, with $5.5B investing outflows and no share repurchases
- Outlook headwinds: elevated utilization, PBM pricing pressure, regulatory changes, inflation, tariffs and weaker discretionary spending
Risk Factors
- Newly added separation risk triggered by November 4, 2026 announcement to create CVS Health and CVS Pharmacy
- Operational risk: management distraction from separation could disrupt ongoing business and adversely affect results
- Regulatory and tax risk: separation requires SEC Form 10 effectiveness and confirmation of tax-free treatment
- Execution risk: separation expected first half of 2028, subject to Board approval and independent-company readiness
- Financial risk: dis-synergy, restructuring and transaction costs could exceed estimates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CVS Health quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.